最有价值和最强大的制药、医疗器械和医疗服务品牌的2026年度报告（英）2026

Healthcare2026 The annual report on the most valuable and strongest pharma, medical devicesand healthcare services brands AboutBrand Finance Bridging the gap betweenMarketing and Finance Brand Finance was set up in 1996 with theaim of 'bridging the gap between marketingand finance'. For more than 25 years, we Quantifying the We put thousands of the world’s biggestbrands to the test every year. Rankingbrands across all sectors and countries, Unique combination The world'sleading brandvaluation Our teams have experienceacross a wide range of disciplinesfrom marketing and market research, Priding ourselveson technical credibility Brand Finance, a chartered accountancyfirm regulated by the Institute of CharteredAccountants in England and Wales, is thefirst brand valuation consultancy to join theInternational Valuation Standards Council. For business enquiries, please contact:enquiries@brandfinance.com For media enquiries, please contact:press@brandfinance.com +44 207 389 9400www.brandfinance.com Contents ForewordDavid Haigh, Chairman & CEO, Brand Finance Sector Overview6 Valuation Analysis9 Most Valuable Pharma Brands 202611Fastest Growing Brand Value:Amgen12Brands to Watch:Novo Nordisk vs Lilly13 Brand Strength Analysis14 Medical DevicesBrand Value & Strength Analysis Healthcare ServicesBrand Value & Strength Analysis Chinese PharmaBrand Value & Strength Analysis Insight The economics of trust: Why reputation isthe hard currency of healthcare and pharmaDr. Markus Renner, PhD, Chairman, International Brand& Reputation Community (INBREC) Pharma | Brand Value Ranking (USDm) Medical Devices | Brand Value Ranking (USDm) Methodology36 Healthcare brandsnavigate innovation, +Pharmaceutical leaders of 2026:Johnson & Johnson, Lilly, andRochehold top spots +Amgen accelerates brand value growth throughdiversification and pipeline strength +LillyvsNovo: A tale of shifting fortunes inweight-loss brands +Johnson & Johnsonis the strongest pharmaceuticalbrand globally, whileSamsung BiologicsandTong Ren +Medtronicextends medical devices lead throughinnovation-led growth +UnitedHealthcareretains healthcare servicesleadership amid heightened scrutiny +Guangzhou Pharmaceuticalstands out asfastest-growing Chinese pharmaceutical brand Foreword This year marks Brand Finance’s 30thanniversary. Throughout our history as acompany, there has been one enduring truism: brands operate in a world shapedby continual change. Rapid advancements in AI, geopolitical fragmentation, economic uncertainty,and rising expectations of corporate behaviour have all placed new pressureson organisations. While the challenges have evolved, the importance of building Looking back to 1996, the global brand landscape was dominated by traditionalconsumer names. Since then, the rise of technology and digital services, the movefrom products to ecosystems, the increasing prominence of B2B brands, and the David HaighChairman & CEO,Brand Finance Today, the commercial contribution of a strong brand is well recognised. It drivesdemand, supports premium pricing, attracts and retains talent, increases resilienceduring uncertainty, and provides confidence to investors. Despite this awareness,many organisations still struggle to quantify brand value or explain its role in business At Brand Finance, our mission for 30 years has been to close that gap. By bringingtogether robust valuation methodologies and in-depth research, we help leadersunderstand the financial impact of their brand and make better-informed decisions.Whether you are looking to strengthen brand performance, evaluate marketing As you explore this year’s findings, I encourage you to consider how the insightscan support clearer decision-making within your organisation. Strong brands arebuilt through informed choices and consistent investment, and our team is ready SectorOverview SectorOverview The pharmaceutical industry has remainedresilient over the past year, with the collective China, accounting for 10%, continues tostrengthen its global footprint as domestic playerssuch asSinopharmandGuangzhou Pharmaceutical The expansion of the ranking from 25 to 50 globalbrands reflects the sector’s increasing breadth aswell as sustained investment in innovation despite Mergers and acquisitions remain a definingfeature of the sector. Pharmaceutical companiesare increasingly using consolidation to strengthenpipelines, offset patent expiries, and gain access to The US continues to dominate the globalpharmaceutical landscape, accounting for 48%of brands in the ranking, reflecting its leadership in Innovation continues to be the primary driver ofbrand value growth. Breakthrough drugs, particularlyin metabolic health, oncology, and immunology, have Switzerland follows with 11%, underlining theenduring strength of its multinational pharmaceutical SectorOverview brand value rising by 4%, supported byadvances in AI-driven diagnostics, minimally invasiveprocedures, and conn